Qynapse Releases Data Highlighting the Accuracy of QyScore® and Predictive performance of QyPredict® for Disease Progression in preclinical Alzheimer’s Disease
TORONTO, July 28, 2025 /PRNewswire/ — Qynapse, a technology company using AI to enhance the quantification and predictive capabilities of imaging to improve outcomes for neurological diseases, including Alzheimer’s disease (AD), presented new data at the Alzheimer’s Association International Conference (AAIC) for QyScore® and QyPredict®. QyScore® is an FDA-cleared and CE-marked proprietary neuroimaging software platform that






